ORL-1 Inhibitors
2 drugsAbout ORL-1
The opioid receptor-like 1 receptor (ORL-1) modulates pain pathways, making it a protein target of interest for pain management.
ORL-1 is a viable therapeutic target for pain, evidenced by two approved drugs, BUPRENORPHINE and BUTRANS. Currently, there is no genetic evidence data available linking ORL-1 to specific diseases.
ORL-1 is targeted by two FDA-approved small molecule drugs, BUPRENORPHINE and BUTRANS, both indicated for pain relief. WATSON LABS TEVA and PURDUE PHARMA LP are the companies marketing these drugs.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Depression with only 2 trials.
Top ORL-1 Drugs
Only two companies, WATSON LABS TEVA and PURDUE PHARMA LP, have approved drugs targeting ORL-1.
Low market concentration suggests an opportunity for new entrants to gain market share.
ORL-1 Drug Modality Landscape
Modalities
Routes of Administration
ORL-1 is druggable by small molecules, though no oral formulations are currently approved.
Explore opportunities for novel modalities like antibodies or peptides to differentiate from existing treatments.
ORL-1 Clinical Trials 205 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 41 | 34 | 3 | 4 | 92% |
| Phase 2 | 47 | 31 | 6 | 9 | 84% |
| Phase 3 | 45 | 29 | 9 | 6 | 76% |
| Phase 4 | 72 | 37 | 13 | 21 | 74% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
ORL-1 Drug Approval Timeline (2010 - 2018)
The first drug targeting ORL-1 was approved in 2010, and the most recent in 2018.
Slow approval rate indicates a potentially challenging development path or limited investment in this target.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 117 clinical trials targeting ORL-1.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities